Orexo Dirección

Dirección controles de criterios 2/4

El CEO de Orexo es Nikolaj Sorensen , nombrado en Feb 2013, tiene una permanencia de 11.75 años. compensación anual total es SEK6.12M, compuesta por 59.5% salario y 40.5% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.52% de las acciones de la empresa, por valor de SEK1.69M. La antigüedad media del equipo directivo y de la junta directiva es de 5.8 años y 4.6 años, respectivamente.

Información clave

Nikolaj Sorensen

Chief Executive Officer (CEO)

SEK 6.1m

Compensación total

Porcentaje del salario del CEO	59.5%
Permanencia del CEO	11.8yrs
Participación del CEO	0.5%
Permanencia media de la dirección	5.8yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Nikolaj Sorensen en comparación con los beneficios de Orexo?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-SEK 105m
Jun 30 2024	n/a	n/a	-SEK 97m
Mar 31 2024	n/a	n/a	-SEK 73m
Dec 31 2023	SEK 6m	SEK 4m	-SEK 128m
Sep 30 2023	n/a	n/a	-SEK 201m
Jun 30 2023	n/a	n/a	-SEK 195m
Mar 31 2023	n/a	n/a	-SEK 218m
Dec 31 2022	SEK 6m	SEK 4m	-SEK 178m
Sep 30 2022	n/a	n/a	-SEK 152m
Jun 30 2022	n/a	n/a	-SEK 177m
Mar 31 2022	n/a	n/a	-SEK 216m
Dec 31 2021	SEK 10m	SEK 4m	-SEK 223m
Sep 30 2021	n/a	n/a	-SEK 207m
Jun 30 2021	n/a	n/a	-SEK 240m
Mar 31 2021	n/a	n/a	-SEK 198m
Dec 31 2020	SEK 9m	SEK 3m	-SEK 84m
Sep 30 2020	n/a	n/a	SEK 4m
Jun 30 2020	n/a	n/a	SEK 201m
Mar 31 2020	n/a	n/a	SEK 288m
Dec 31 2019	SEK 6m	SEK 3m	SEK 219m
Sep 30 2019	n/a	n/a	SEK 232m
Jun 30 2019	n/a	n/a	SEK 182m
Mar 31 2019	n/a	n/a	SEK 178m
Dec 31 2018	SEK 5m	SEK 3m	SEK 138m
Sep 30 2018	n/a	n/a	SEK 113m
Jun 30 2018	n/a	n/a	SEK 79m
Mar 31 2018	n/a	n/a	SEK 32m
Dec 31 2017	SEK 6m	SEK 4m	SEK 23m

Compensación vs. Mercado: La compensación total de Nikolaj($USD560.19K) está por encima de la media de empresas de tamaño similar en el mercado UK ($USD358.38K).

Compensación vs. Ingresos: La compensación de Nikolaj ha aumentado mientras la empresa no es rentable.

CEO

Nikolaj Sorensen (52 yo)

11.8yrs

Permanencia

SEK 6,118,000

Compensación

Mr. Nikolaj Sørensen serves as Independent Director at Bioservo Technologies AB (publ) since May 6, 2019. He is Director at Gesynta Pharma AB. He has been the Chief Executive Officer of Orexo AB since Febr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Nikolaj Sorensen	President & CEO	11.8yrs	SEK 6.12m	0.52% SEK 1.7m
Fredrik Jarrsten	Executive VP & CFO	2.3yrs	sin datos	0.076% SEK 246.2k
Cecilia Coupland	Senior VP & Head of Operations	5.8yrs	sin datos	0.042% SEK 135.3k
Lena Wange	Investor Relations & Communications Director	no data	sin datos	sin datos
Robert Ronn	Senior VP and Head of R&D	5.8yrs	sin datos	0.059% SEK 190.6k
Edward Kim	Chief Medical Officer	2.1yrs	sin datos	sin datos
Robert Deluca	President of Orexo US Inc	11.8yrs	sin datos	0.051% SEK 165.3k
Jesper Lind	Advisor	no data	sin datos	sin datos

5.8yrs

Permanencia media

54.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0H19 es experimentado (5.8 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
George Wilkinson	Independent Director	5.6yrs	SEK 400.00k	0.056% SEK 180.5k
James Noble	Independent Chairman of the Board	4.6yrs	SEK 1.50m	0.19% SEK 606.4k
Staffan Lindstrand	Independent Director	22.8yrs	SEK 450.00k	0.099% SEK 320.9k
Christine Rankin	Independent Director	2.6yrs	SEK 550.00k	0.023% SEK 74.5k
Robin Evers	Independent Director	1.1yrs	SEK 50.00k	sin datos

4.6yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de 0H19 se considera experimentada (4.6 años de antigüedad promedio).

Orexo Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Orexo AB (publ) Announces Nomination Committee for the Annual General Meeting 2025

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

Independent Chairman of the Board recently bought kr361k worth of stock

Recent updates

No longer forecast to breakeven

New major risk - Negative shareholders equity

Third quarter 2024 earnings released: kr1.21 loss per share (vs kr0.97 loss in 3Q 2023)

Orexo AB (publ) Initiates New Study of OX640 in Participants with Allergic Rhinitis

Orexo AB (publ) Announces Nomination Committee for the Annual General Meeting 2025

Second quarter 2024 earnings released: kr1.04 loss per share (vs kr0.37 loss in 2Q 2023)

Orexo AB (publ) to Report Q1, 2025 Results on May 06, 2025

Independent Director recently bought kr94k worth of stock

Independent Director recently bought kr70k worth of stock

Orexo AB (publ) to Report Q3, 2024 Results on Oct 24, 2024

First quarter 2024 earnings released: kr0.26 loss per share (vs kr1.86 loss in 1Q 2023)

Orexo Extends Patent Protection for Its Nasal Epinephrine Powder Product OX640 in the US

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (Publ) Announces Board Resignations

President & CEO recently bought kr148k worth of stock

New major risk - Financial position

Full year 2023 earnings released: kr3.73 loss per share (vs kr5.17 loss in FY 2022)

Orexo AB (publ) to Report Q4, 2024 Results on Feb 06, 2025

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Orexo AB (Publ) Announces FDA Acceptance of New Drug Application Filing for OX124

Independent Chairman of the Board recently bought kr361k worth of stock

New minor risk - Profitability

No longer forecast to breakeven

Executive VP & CFO recently bought kr81k worth of stock

Third quarter 2023 earnings released

Orexo AB (publ) Announces Changes in the Board of Directors

Orexo AB (publ), Annual General Meeting, Apr 26, 2024

Orexo AB (publ) Announces Data from the MODIA Study Evaluating Impact on Use of Illicit Opioids

Orexo AB (Publ) Announces Henrik Kjær Hansen Will Resign from the Board of Directors

Orexo AB (publ) to Report Q2, 2024 Results on Jul 17, 2024

Orexo AB (publ.) Submits New Drug Application to FDA for OX124, a High-Dose Rescue Medication for Opioid Over Overio Overio Overio Overio

President & CEO recently bought kr74k worth of stock

Second quarter 2023 earnings released

New major risk - Revenue and earnings growth

New major risk - Share price stability

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released

President & CEO recently bought kr189k worth of stock

Orexo AB (publ) Submits New Drug Application to FDA for OX124, A High-Dose Rescue Medication for Opioid Overdose

Full year 2022 earnings released: kr5.17 loss per share (vs kr6.51 loss in FY 2021)

Orexo AB (publ.) Initiates Exploratory Feasibility Studies of amorphOX with Two Leading Biopharmaceutical and Vaccine Companies

Orexo AB (publ) to Report Fiscal Year 2022 Final Results on Mar 28, 2023

Third quarter 2022 earnings released

Orexo AB (publ) Announces Last Patient Enrolled in Pivotal Study Evaluating the Efficacy of MODIA® in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Orexo AB (publ) Appoints Edward Kim, M.D., as New Chief Medical Officer

Orexo AB (publ), Annual General Meeting, Apr 18, 2023

Orexo Announces Positive Data from Phase 1 Clinical Study for OX640

Orexo AB (publ) to Report Q1, 2023 Results on Apr 27, 2023

Independent Director recently bought kr60k worth of stock

Second quarter 2022 earnings released

Orexo AB (Publ.) Announces Successfully Initiated the First Explorative Human Clinical Study for Ox640

First quarter 2022 earnings released

Orexo AB (publ) Announces Board Appointments

Full year 2021 earnings released: kr6.51 loss per share (vs kr2.45 loss in FY 2020)

Director recently bought kr505k worth of stock

President & CEO recently bought kr243k worth of stock

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Orexo AB (publ) to Report Q4, 2022 Results on Jan 26, 2023

Orexo AB (Publ.) Develops Nasal Adrenaline Medication Based on the Novel Amorphox Platform

Orexo AB Provides Information About Its New Proprietary Drug Delivery Platform - Amorphox

Third quarter 2021 earnings released: kr1.52 loss per share (vs kr2.45 loss in 3Q 2020)

Second quarter 2021 earnings released: kr2.15 loss per share (vs kr0.94 loss in 2Q 2020)

Orexo AB (Publ) Pharmaceutical Pipeline Asset Ox124 Enters Pivotal Trial

Orexo Announces First Patient Enrolled in Pivotal Study Evaluating the Efficacy of Modia™ in Combination with Sublingual Buprenorphine/ Naloxone for the Treatment of OUD

Independent Director recently bought kr61k worth of stock

Independent Director recently bought kr103k worth of stock

Independent Director recently bought kr103k worth of stock

Independent Chairman of the Board recently bought kr409k worth of stock

President & CEO recently bought kr400k worth of stock